Linked Life Data

15837036

Source:http://linkedlifedata.com/resource/pubmed/id/15837036

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2005-4-19
pubmed:abstractText
In 2002, the UK National Institute for Clinical Excellence (NICE) issued guidance on the use of irinotecan, oxaliplatin and raltitrexed in advanced colorectal cancer. This guidance recommended that UK patients with advanced colorectal cancer (CRC) receive 5-FU+folinic acid [leucovorin] as first line therapy, and were only eligible for irinotecan if their disease progressed. NICE guidance is adopted worldwide by more than 25 countries in addition to the British National Health Service. This guidance specifically recommended that, 'oxaliplatin could be used in first line treatment if in the opinion of an experienced liver surgeon, a patient might become potentially resectable'. Since 2002, the definition of hepatic resectability with curative intent for these patients has changed radically to encompass any patient in whom a 70% liver resection will achieve total macroscopic removal of all liver disease. Furthermore, compelling evidence has emerged over the last 2 years, which clearly demonstrates the therapeutic superiority of oxaliplatin and irinotecan based regimens over 5FU and leucovorin in the treatment of patients with advanced colorectal cancer. The original guidance was not due for review until 2007, presently NICE are reviewing this guidance prematurely, and new guidance will be issued by the summer of 2005, and clearly this review will have an impact in many countries. This paper summarises the present evidence for the use of these regimens. Most importantly, it is now a prerequisite for liver surgeons to work hand in hand with medical oncologists to obtain maximum survival benefit and increased chance of cure for these patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0748-7983
pubmed:author
pubmed:issnType
Print
pubmed:volume
31
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
325-30
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
The use of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer.
pubmed:affiliation
University Hospital Aintree, Liverpool L9 7AL, UK. graemeposton@blueyonder.co.uk
pubmed:publicationType
Journal Article, Review